SEC Form 4 · accession 0001214659-26-010516
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Barber
Officer — President and CEO · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2026 | S | 25,000 | $4.2867 | D | 585,574 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction involves sale transactions from $4.24 to $4.35 per share. The weighted average price per share was $4.2867. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.